Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Granger

Showing results (881-890 of 1,023) with videos related to

Pageof 103
Sort By:
JAMA Cardiology|March 30, 2017
Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical TrialPatricia A Cowper, Shubin Sheng, Renato D Lopes, et al.
JACC. Advances|August 12, 2024
Combinations of First Responder and Drone Delivery to Achieve 5-Minute AED Deployment in OHCAMonique A Starks, Jamal Chu, K H Benjamin Leung, et al.
American Heart Journal|August 13, 2011
Recalibration of the Global Registry of Acute Coronary Events risk score in a multiethnic Asian populationMark Y Chan, Bimal R Shah, Fei Gao, et al.
American Heart Journal|March 31, 2000
Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitorsC B Granger, G Ertl, J Kuch, et al.
Journal of the American Heart Association|December 3, 2015
Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) TrialMeena P Rao, Sigrun Halvorsen, Daniel Wojdyla, et al.
Journal of the American College of Cardiology|March 10, 2018
Digoxin and Mortality in Patients With Atrial FibrillationRenato D Lopes, Roberto Rordorf, Gaetano M De Ferrari, et al.
Circulation|September 4, 2024
Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA TrialWilliam F McIntyre, Alexander P Benz, Jeff S Healey, et al.
American Heart Journal|September 19, 2020
Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AFib)Sana M Al-Khatib, Sean D Pokorney, Hussein R Al-Khalidi, et al.
European Journal of Heart Failure|September 2, 2022
Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trialOtavio Berwanger, Marc Pfeffer, Brian Claggett, et al.
European Heart Journal|December 16, 2014
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trialClaes Held, Elaine M Hylek, John H Alexander, et al.
Pageof 103

Showing results (881-890 of 1,023) with videos related to

Sort By:
Pageof 103
JAMA Cardiology|March 30, 2017
Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical TrialPatricia A Cowper, Shubin Sheng, Renato D Lopes, et al.
JACC. Advances|August 12, 2024
Combinations of First Responder and Drone Delivery to Achieve 5-Minute AED Deployment in OHCAMonique A Starks, Jamal Chu, K H Benjamin Leung, et al.
American Heart Journal|August 13, 2011
Recalibration of the Global Registry of Acute Coronary Events risk score in a multiethnic Asian populationMark Y Chan, Bimal R Shah, Fei Gao, et al.
American Heart Journal|March 31, 2000
Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitorsC B Granger, G Ertl, J Kuch, et al.
Journal of the American Heart Association|December 3, 2015
Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) TrialMeena P Rao, Sigrun Halvorsen, Daniel Wojdyla, et al.
Journal of the American College of Cardiology|March 10, 2018
Digoxin and Mortality in Patients With Atrial FibrillationRenato D Lopes, Roberto Rordorf, Gaetano M De Ferrari, et al.
Circulation|September 4, 2024
Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA TrialWilliam F McIntyre, Alexander P Benz, Jeff S Healey, et al.
American Heart Journal|September 19, 2020
Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AFib)Sana M Al-Khatib, Sean D Pokorney, Hussein R Al-Khalidi, et al.
European Journal of Heart Failure|September 2, 2022
Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trialOtavio Berwanger, Marc Pfeffer, Brian Claggett, et al.
European Heart Journal|December 16, 2014
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trialClaes Held, Elaine M Hylek, John H Alexander, et al.
Pageof 103